Abbott Laboratories (ABT) Posted Higher Sensitivity Data For Colorectal Cancer Recurrence Detection

Abbott Laboratories (NYSE:ABT) reported new Beta-CORRECT study data on its Oncodetect test at ESMO 2026. The Beta-CORRECT trial showed a significant sensitivity improvement for detecting colorectal cancer recurrence using circulating tumor DNA. The Oncodetect assay targets low levels of tumor DNA in the bloodstream to support closer monitoring of patients after colorectal surgery. The sensitivity gains for Oncodetect in the Beta-CORRECT study are important, but investors should weigh them...